Working… Menu

High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 (VIRID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00662220
Recruitment Status : Terminated (Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study had to be terminated.)
First Posted : April 21, 2008
Last Update Posted : July 14, 2014
Hoffmann-La Roche
Information provided by (Responsible Party):
Foundation for Liver Research

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : June 2013
Actual Study Completion Date : November 2013